Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
Thürlimann B, Hess D, Köberle D, Senn I, Ballabeni P, Pagani O, Perey L, Aebi S, Rochlitz C, Goldhirsch A. Thürlimann B, et al. Breast Cancer Res Treat. 2004 Jun;85(3):247-54. doi: 10.1023/B:BREA.0000025420.78346.f9. Breast Cancer Res Treat. 2004. PMID: 15111763 Clinical Trial.
Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?
Sabbioni ME, Bernhard J, Siegrist HP, Schmitz SF, Gertsch MC, Thürlimann B, Bonnefoi H, Perey L, Herrmann R, Goldhirsch A, Hürny C; Swiss Group for Clinical Cancer Research (SAKK). Sabbioni ME, et al. Among authors: thurlimann b. Breast Cancer Res Treat. 2004 Sep;87(1):75-86. doi: 10.1023/B:BREA.0000041584.53863.a7. Breast Cancer Res Treat. 2004. PMID: 15377853 Free article. Clinical Trial.
Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93.
Thürlimann B, Price KN, Gelber RD, Holmberg SB, Crivellari D, Colleoni M, Collins J, Forbes JF, Castiglione-Gertsch M, Coates AS, Goldhirsch A; International Breast Cancer Study Group. Thürlimann B, et al. Breast Cancer Res Treat. 2009 Jan;113(1):137-44. doi: 10.1007/s10549-008-9912-9. Epub 2008 Feb 8. Breast Cancer Res Treat. 2009. PMID: 18259856 Free PMC article. Clinical Trial.
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.
Pagani O, Gelber S, Simoncini E, Castiglione-Gertsch M, Price KN, Gelber RD, Holmberg SB, Crivellari D, Collins J, Lindtner J, Thürlimann B, Fey MF, Murray E, Forbes JF, Coates AS, Goldhirsch A; International Breast Cancer Study Group. Pagani O, et al. Among authors: thurlimann b. Breast Cancer Res Treat. 2009 Aug;116(3):491-500. doi: 10.1007/s10549-008-0225-9. Epub 2008 Oct 25. Breast Cancer Res Treat. 2009. PMID: 18953651 Free PMC article. Clinical Trial.
Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century.
Pagani O, Price KN, Gelber RD, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Thürlimann B, Collins J, Fey MF, Coates AS, Goldhirsch A; International Breast Cancer Study Group (IBCSG). Pagani O, et al. Among authors: thurlimann b. Breast Cancer Res Treat. 2009 Sep;117(2):319-24. doi: 10.1007/s10549-008-0282-0. Epub 2009 Jan 10. Breast Cancer Res Treat. 2009. PMID: 19137426 Free PMC article.
Update of the BIG 1-98 Trial: where do we stand?
Joerger M, Thürlimann B. Joerger M, et al. Among authors: thurlimann b. Breast. 2009 Oct;18 Suppl 3:S78-82. doi: 10.1016/S0960-9776(09)70278-4. Breast. 2009. PMID: 19914548 Free article. Clinical Trial.
234 results